标题：大剂量瑞舒伐他汀对急性心肌梗死患者血清MMP-9、hs-CRP及心室重构的影响

      作者：高 刻
    (淮安市第一人民医院一分院，江苏 淮安 223002)

      卷次： 2015年26卷19期

      【摘要】 目的 分析大剂量瑞舒伐他汀对急性心肌梗死(AMI)患者血清基质金属蛋白酶-9 (MMP-9)、血
清高敏C反应蛋白(hs-CRP)及心室重构的影响。方法 选择 2012年 2月至 2014年 2月我院收治的AMI住院
患者 110例，随机分为观察组与对照组，每组各 55例。两组均给予AMI常规治疗，再次基础上，观察组应用
20 mg/d的瑞舒伐他汀治疗，对照组应用 10 mg/d的瑞舒伐他汀治疗。分别于治疗后 24 h、16周测定两组患者
的血清MMP-9、hs-CRP和超声心动图变化。结果 治疗 16周后，观察组组MMP-9、hs-CRP水平显著低于对
照组，且低于治疗 24 h，差异均有显著统计学意义(P<0.01)；两组治疗24 h时各项超声心动图指标变化差异无统
计学意义(P>0.05)；治疗16周后，观察组左室收缩期末内径(LVESD)、左室舒张期末内径(LVEDD)、左室收缩末期
容积(LVESV)、左室舒张末期容积(LVEDV)水平显著低于对照组及治疗24 h时，左室短轴缩短分数(FS)、左室射
血分数(LVEF)水平显著高于对照组及治疗24 h，差异均有显著统计学意义(P<0.01)。结论 应用大剂量瑞舒伐
他汀治疗AMI可以有效降低MMP-9、hs-CRP水平，抑制心室重构，安全可靠，保障了患者的心功能。

      【关键词】 大剂量；瑞舒伐他汀；急性心肌梗死；MMP-9；hs-CRP；心室重构

      【中图分类号】 R542.2+2 【文献标识码】 A 【文章编号】 1003—6350（2015）19—2821—03


Effect of large dose of rosuvastatin on serum MMP-9, hs-CRP and ventricular remodeling in patients of acute
myocardial infarction.
GAO Ke. First Branch of Huai'an First People's Hospital, Huai'an 223002, Jiangsu, CHINA

【Abstract】 Objective To analyze the effect of large dose of rosuvastatin on serum matrix metalloprotein-9
(MMP-9), high-sensitivity C-reactive protein (hs-CRP) and ventricular remodeling in patients with acute myocardial
infarction (AMI). Methods One hundred and ten hospitalized patients with AMI in our hospital from February 2012
to February 2014 were selected, which were randomly divided into observation group and control group, with 55 cases
in each group. On the basis of conventional treatment, the observation group applied 20 mg/d rosuvastatin for treat-
ment, and the control group used 10 mg/d rosuvastatin. The changes in serum MMP-9, hs-CRP and ultrasound Beck-
oning map 24 h, 16 weeks after treatment were investigated. Results 16 weeks after treatment, the levels of hs-CRP,
MMP-9 in the observation group were significantly lower than those in the control group, which were also lower than
those 24 h after treatment (P<0.01). 24 h after treatment, the ultrasonic Heartbeat figure index changes showed no sta-
tistically significant difference between the two groups (P>0.05). 16 weeks after treatment, the left ventricular end sys-
tolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD), left ventricular end systolic volume
(LVESV), left ventricular end diastolic volume (LVEDV) of the observation group were significantly lower than those
of the control group and those 24 h after treatment (P<0.01). Left ventricular fractional shortening (FS) and left ven-
tricular ejection fraction (LVEF) were significantly higher than those in the control group (24 h), and the difference
was statistically significant (P<0.01). Conclusion Large dose of rosuvastatin can, with safety, effectively reduce
AMI, MMP-9, hs-CRP levels, inhibit left ventricular remodeling, and protect the heart function of patients.

      【Key words】 Large dose; Rosuvastatin; Acute myocardial infarction; Matrix metalloprotein-9 (MMP-9);